Incidence of circulating cells positive for GpIb and GpIIIa in infants with Down's syndrome

Area of Science:

• Hematology
• Genetics
• Pediatrics

Background:

• Down's syndrome is associated with an increased risk of certain cancers, including leukemia.
• Platelet glycoproteins, such as GpIb and GpIIIa, play roles in cell adhesion and signaling.
• Circulating cells expressing platelet glycoprotein markers have been investigated in various hematological conditions.

Purpose of the Study:

• To investigate the presence and quantity of cells positive for platelet glycoproteins GpIb and GpIIIa in infants with Down's syndrome.
• To compare these findings with those in infants with a normal karyotype.
• To explore potential associations between these markers and leukemia in infants with Down's syndrome.

Main Methods:

• Blood samples were collected from 43 infants with Down's syndrome and 67 controls.
• Samples were screened for cells positive for platelet glycoproteins GpIb and GpIIIa using immunophenotyping.
• Leukemia cases within the Down's syndrome cohort were identified and analyzed.

Main Results:

• Two cases of leukemia (one fatal, one transient) were identified in the Down's syndrome group.
• Both leukemia cases showed increased numbers of circulating cells positive for platelet glycoprotein markers.
• Small numbers of these marker-positive cells were detected in both Down's syndrome and control groups, with no significant difference between them, even in stillbirths.

Conclusions:

• The presence of circulating cells positive for platelet glycoprotein markers does not appear to be significantly elevated in infants with Down's syndrome compared to controls.
• While leukemia cases in Down's syndrome patients showed increased marker-positive cells, this finding requires further investigation in larger cohorts.
• The study suggests that these specific platelet glycoprotein markers may not be a primary indicator for increased leukemia risk in the general Down's syndrome population.